All In Biotech

Drug Trial Radar · NCT07094516

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

96

Actual

Start

Aug 7, 2025

Primary completion

Sep 14, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

Conditions

  • Alzheimer's Disease

Interventions

  • VHB937Biological

    VHB937 solution for infusion

  • VHB937Biological

    VHB937 solution for infusion

  • PlaceboOther

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the Clinical Dementia Rating scale - Sum of Boxes (CDR-SB)Time frame: Baseline and Week 72

Locations

73 sites in 15 countries. Site status is shown where the registry gives one.

  • Banner Alzheimers Institute

    Phoenix, Arizona

  • Irvine Center for Clinical Research

    Irvine, California

  • University of California San Diego

    La Jolla, California

  • University of California at Los Angeles

    Los Angeles, California

  • Jem Research Institute

    Atlantis, Florida

  • Visionary Investigators Network

    Aventura, Florida

  • K2 Medical Research LLC

    Maitland, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Charter Research The Villages

    The Villages, Florida

  • Alzheimers Research Treatment Ctr

    Wellington, Florida

  • Conquest Research

    Winter Park, Florida

  • Hawaii Pacific Neuroscience LLC

    Honolulu, Hawaii

  • University of Kansas Hospital

    Fairway, Kansas

  • ActivMed Practices and Research

    Methuen, Massachusetts

  • Citizens Memorial Hospital Neurology CLinic

    Bolivar, Missouri

  • Lou Ruvo Center for Brain Health

    Las Vegas, Nevada

  • UNC Hosp Invest Drug Serv Pharm

    Chapel Hill, North Carolina

  • The Ohio State University

    Columbus, Ohio

  • Neural Net Research

    Portland, Oregon

  • Abington Neurological Associates Ltd

    Willow Grove, Pennsylvania

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • University of Washington Medical Center

    Seattle, Washington

  • Novartis Investigative Site

    Camperdown, New South Wales, Australia

  • Novartis Investigative Site

    Kogarah, New South Wales, Australia

  • Novartis Investigative Site

    Box Hill, Victoria, Australia

  • Novartis Investigative Site

    Heidelberg, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    London, Ontario, Canada

  • Novartis Investigative Site

    North York, Ontario, Canada

  • Novartis Investigative Site

    Ottawa, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Toulouse, Haute Garonne, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    München, Germany

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.